Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors

You should discuss cancer concerns with your GP or specialist before starting a GLP-1 medicine if you have: Personal history of any cancer, particularly thyroid or pancreatic malignancies Family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 Previous episodes of pancreatitis Unexplained symptoms such as persistent abdominal pain, neck lumps, or difficulty swallowing Anxiety about cancer risk that may affect medicine adherence During treatment with a GLP-1 medicine, contact your healthcare provider promptly if you develop: A lump or swelling in the neck Persistent hoarseness or voice changes Difficulty swallowing or breathing Severe, persistent abdominal pain, especially if radiating to the back (seek urgent medical help via NHS 111 or A&E if severe) Unexpected or disproportionate weight loss relative to your dose and treatment plan, especially with other concerning symptoms Any other worrying symptoms It is important to maintain perspective: the proven cardiovascular benefits of GLP-1 medicines in reducing heart attack, stroke, and cardiovascular death substantially outweigh theoretical cancer concerns for most patients

Goldney, J., Hamza, M., Surti, F., Davies, M
But Pennsylvania isnt alone in pursuing the policy shift
What are the risks of using GLP-1 (Glucagon-like peptide-1) receptor agonists, such as liraglutide (Victoza) or semaglutide (Ozempic), in a patient with decompensated cirrhosis and a history of multiple thyroid nodules, and why are they avoided at this stage?
Incretin-based drugs work by restoring that signal pharmacologically